A functional polymorphism in PER3 gene is associated with prognosis in hepatocellular carcinoma

Liver International

Volumn 32, Issue 9, 2012, Pages 1451-1459

  Zhao, Binyu ^a   Lu, Jianguo ^a   Yin, Jikai ^a   Liu, Hanqiang ^b   Guo, Xu ^b   Yang, Yefa ^c   Ge, Naijian ^c   Zhu, Yong ^d   Zhang, Hongxin ^a   Xing, Jinliang ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Circadian gene; Hepatocellular carcinoma; Prognosis; Single nucleotide polymorphism

Indexed keywords

ANTINEOPLASTIC AGENT; CRYPTOCHROME 1; CRYPTOCHROME 2; PER1 PROTEIN; PER2 PROTEIN; PER3 PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; CANCER IMMUNOLOGY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHINESE; COHORT ANALYSIS; FEMALE; GAMMA KNIFE RADIOSURGERY; GENETIC ASSOCIATION; GENOTYPE; GENOTYPING TECHNIQUE; HOMOZYGOSITY; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; RADIOFREQUENCY ABLATION; RADIOIMMUNOTHERAPY; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CHINA; CIRCADIAN RHYTHM; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; PERIOD CIRCADIAN PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

EID: 84865715920     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2012.02849.x     Document Type: Article

References (38)

1. Fan J, Yu Y, Wu Z. Liver resection after transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma and curative effect analysis. Zhonghua Wai Ke Za Zhi 1997; 35: 710-2.
2. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004; 127: S179-88.
3. Lau WY, Yu SC, Lai EC, Leung TW. Transarterial chemoembolization for hepatocellular carcinoma. J Am Coll Surg 2006; 202: 155-68.
4. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
5. Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27: 1578-83.
6. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-71.
7. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-9.
8. Dibner C, Schibler U, Albrecht U. The mammalian circadian timing system: organization and coordination of central and peripheral clocks. Annu Rev Physiol 2010; 72: 517-49.
9. Lowrey PL, Takahashi JS. Mammalian circadian biology: elucidating genome-wide levels of temporal organization. Annu Rev Genomics Hum Genet 2004; 5: 407-41.
10. Kondratov RV, Gorbacheva VY, Antoch MP. The role of mammalian circadian proteins in normal physiology and genotoxic stress responses. Curr Top Dev Biol 2007; 78: 173-216.
11. Lee C, Etchegaray JP, Cagampang FR, Loudon AS, Reppert SM. Posttranslational mechanisms regulate the mammalian circadian clock. Cell 2001; 107: 855-67.
12. Kondratov RV, Chernov MV, Kondratova AA, et al. BMAL1-dependent circadian oscillation of nuclear CLOCK: posttranslational events induced by dimerization of transcriptional activators of the mammalian clock system. Genes Dev 2003; 17: 1921-32.
13. DeBruyne JP, Weaver DR, Reppert SM. CLOCK and NPAS2 have overlapping roles in the suprachiasmatic circadian clock. Nat Neurosci 2007; 10: 543-5.
14. Asher G, Schibler U. A CLOCK-less clock. Trends Cell Biol. 2006; 16: 547-9.
15. Kume K, Zylka MJ, Sriram S, et al. mCRY1 and mCRY2 are essential components of the negative limb of the circadian clock feedback loop. Cell 1999; 98: 193-205.
16. Dunlap JC. Molecular bases for circadian clocks. Cell 1999; 96: 271-90.
17. Straif K, Baan R, Grosse Y, et al. Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol 2007; 8: 1065-6.
18. Zhu Y, Leaderer D, Guss C, et al. Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of non-Hodgkin's lymphoma. Int J Cancer 2007; 120: 432-5.
19. Zhu Y, Stevens RG, Leaderer D, et al. Non-synonymous polymorphisms in the circadian gene NPAS2 and breast cancer risk. Breast Cancer Res Treat 2008; 107: 421-5.
20. Yi C, Mu L, de la Longrais IA, et al. The circadian gene NPAS2 is a novel prognostic biomarker for breast cancer. Breast Cancer Res Treat 2010; 120: 663-9.
21. Zhou F, He X, Liu H, et al. Functional polymorphisms of circadian positive feedback regulation genes and clinical outcome of Chinese patients with resected colorectal cancer. Cancer 2012; 118: 937-46.
22. Lin YM, Chang JH, Yeh KT, et al. Disturbance of circadian gene expression in hepatocellular carcinoma. Mol Carcinog 2008; 47: 925-33.
23. Filipski E, King VM, Li X, et al. Host circadian clock as a control point in tumor progression. J Natl Cancer Inst 2002; 94: 690-7.
24. Hoffman AE, Zheng T, Ba Y, Zhu Y. The circadian gene NPAS2, a putative tumor suppressor, is involved in DNA damage response. Mol Cancer Res 2008; 6: 1461-8.
25. Fu L, Pelicano H, Liu J, Huang P, Lee C. The circadian gene Period 2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 2002; 111: 41-50.
26. Zheng B, Albrecht U, Kaasik K, et al. Nonredundant roles of the mPer1 and mPer2 genes in the mammalian circadian clock. Cell 2001; 105: 683-94.
27. Gery S, Koeffler HP. The role of circadian regulation in cancer. Cold Spring Harb Symp Quant Biol 2007; 72: 459-64.
28. Zhu Y, Brown HN, Zhang Y, Stevens RG, Zheng T. Period 3 structural variation: a circadian biomarker associated with breast cancer in young women. Cancer Epidemiol Biomarkers Prev 2005; 14: 268-70.
29. Xu Z, Taylor JA. SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res 2009; 37: W600-5.
30. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
31. Zhu Y, Stevens RG, Hoffman AE, et al. Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study. Cancer Res 2009; 69: 9315-22.
32. Oshima T, Takenoshita S, Akaike M, et al. Expression of circadian genes correlates with liver metastasis and outcomes in colorectal cancer. Oncol Rep 2011; 25: 1439-46.
33. Shi GM, Ke AW, Zhou J, et al. CD151 modulates expression of matrix metalloproteinase 9 and promotes neoangiogenesis and progression of hepatocellular carcinoma. Hepatology 2010; 52: 183-96.
34. Yang XR, Xu Y, Yu B, et al. High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut 2010; 59: 953-62.
35. Im JS, Jung BH, Kim SE, Lee KH, Lee JK. Per3, a circadian gene, is required for Chk2 activation in human cells. FEBS Lett 2010; 584: 4731-4.
36. Costa MJ, So AY, Kaasik K, et al. Circadian rhythm gene period 3 is an inhibitor of the adipocyte cell fate. J Biol Chem 2011; 286: 9063-70.
37. Hull J, Campino S, Rowlands K, et al. Identification of common genetic variation that modulates alternative splicing. PLoS Genet 2007; 3: e99.
38. Yamaguchi S, Shinmura K, Saitoh T, et al. A single nucleotide polymorphism at the splice donor site of the human MYH base excision repair genes results in reduced translation efficiency of its transcripts. Genes Cells 2002; 7: 461-74.